DrugPatentWatch Database Preview

Details for Patent: 8,784,878

« Back to Dashboard

Which drugs does patent 8,784,878 protect, and when does it expire?

Patent 8,784,878 protects AXIRON and is included in one NDA.

This patent has eighteen patent family members in eleven countries.

Summary for Patent: 8,784,878

Title:	Transdermal delivery rate control using amorphous pharmaceutical compositions
Abstract:	A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (C.sub.max) to the average concentration (C.sub.avg) for the physiologically active agent over the dosage interval within the range of 1 to 10.
Inventor(s):	Morgan; Timothy Matthias (Carlton North, AU), Wilkins; Nina Frances (Kensington, AU), Klose; Kathryn Traci-Jane (Bonreach, AU), Finnin; Barrie Charles (Toorak, AU), Reed; Barry Leonard (Essendon, AU)
Assignee:	Acrux DDS Pty Ltc. (West Melbourne, Victoria, AU)
Application Number:	13/710,761
Patent Claim Types: see list of patent claims	Composition; Delivery; Use;

Drugs Protected by US Patent 8,784,878

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Eli Lilly And Co	AXIRON	testosterone	SOLUTION, METERED;TRANSDERMAL	022504-001	Nov 23, 2010		DISCN	Yes	No			Y			A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE

Non-Orange Book US Patents Family Members for Patent 8,784,878

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,357,393	Transdermal delivery rate control using amorphous pharmaceutical compositions

International Family Members for US Patent 8,784,878

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003240301
Brazil	0312007
Brazil	PI0312007
Canada	2489865